Navigation Links
EnduRx Pharmaceuticals to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference

(PRWEB) August 27, 2013

EnduRx Pharmaceuticals, Inc. has been selected to present at the 2013 Rocky Mountain Life Science Investor and Partnering Conference. The conference will take place on September 18-19, 2013 in Denver, Colorado and is hosted by the Colorado BioScience Association. EnduRx Pharmaceuticals is one company chosen to present among thirty from Colorado, Arizona, Utah, Montana, and New Mexico.

         EnduRx Pharmaceuticals, Inc. is a subsidiary of ACTUS Biotechnologies, Inc., an accelerator focused on development of novel technologies into commercially available therapies. The EnduRx Pharmaceuticals platform technology is based upon a modular, multivalent nanotechnology that can be designed to selectively home to vascular tumors, clots, or wounds. The initial use of the platform is focused on the therapeutic treatment of Glioblastoma multiforme (GBM). In pre-clinical models, Endurx Pharmaceuticals’ nanosystem resulted in a 90% success rate in definitive treatment of glioblastoma. Additionally, the system has demonstrated 90% tumor volume reduction in breast cancer, with similar results in prostate cancer, and has proven ability to target a variety of solid vascular tumors. Other uses of the platform technology include atherosclerosis and clots involved in heart attack and stroke, as well as imaging potential in both cancer and cardiovascular disease. EnduRx Pharmaceuticals is currently seeking partners to utilize its proprietary technology to develop the platform in these other indications, using the company’s proof of concept experiments as a basis for development.

         EnduRx Pharmaceuticals, Inc. was founded in 2011 on the basis of proprietary targeting nanoworm technology developed by Dr. Erkki Ruoslahti and his laboratory at the Sanford-Burnham Medical Research Institute ("SBMRI"). Dr. Ruoslahti is among the world's 50 most-cited researchers and an influential figure in cell biology and cancer research. Dr. Ruoslahti’s work has clarified many of the fundamental mechanisms responsible for clinically relevant problems, including tumor metastasis, blood clotting and immune cell homing. His research spawned many drug-discovery programs, some of which have resulted in FDA-approved drugs.

         For more information on EnduRx Pharmaceuticals, visit the company’s website here. Information regarding ACTUS Biotechnologies may be found at the company’s website, here. Additional information on the Rocky Mountain Life Science Investor and Partnering Conference can be found here.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
(Date:11/25/2015)... 2015 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... fireside chat discussion at the Piper Jaffray 27th Annual ... The discussion is scheduled for Wednesday, December 2, at ... A replay will be available for 14 days after ... Julie NormartVP, Corporate Communications and Business Development , BrewLife(858) ...
(Date:11/24/2015)... 2015  Asia-Pacific (APAC) holds the third-largest share ... The trend of outsourcing to low-cost locations is ... volume share for the region in the short ... in the CRO industry will improve. ... ), finds that the market earned revenues ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
Breaking Biology Technology:
(Date:11/20/2015)... OXFORD, Connecticut , November 20, 2015 ... biometric authentication company focused on the growing mobile commerce ... its CEO, Gino Pereira , was recently interviewed ... The interview will air on this weekend on ... Bloomberg Latin America . --> NXTD ) ...
(Date:11/19/2015)... 19, 2015  Although some 350 companies are actively ... a few companies, according to Kalorama Information. These include Roche ... the market share of the 6.1 billion-dollar molecular testing ... Market for Molecular Diagnostic s .    ... still controlled by one company and only a handful ...
(Date:11/18/2015)... --> --> ... report titled  Gesture Recognition Market - Global Industry Analysis, ... to the report, the global gesture recognition market was valued at ... US$29.1 bn by 2021, at a CAGR of 20.3% ... dominated the global gesture recognition market in ...
Breaking Biology News(10 mins):